Close of Accelerated Bookbuild

March 4, 2022
Further to the announcement made at 7.10 a.m. today, the Placing has now closed and the Bookbuild has been successfully concluded.
Keep Reading

Proposed Fundraise to raise not less than £10.0 million (approximately $13.3 million)

March 4, 2022
Verici Dx announces its intention to conduct a fundraise through the non pre-emptive issue of at least 28,571,429 new ordinary shares
Keep Reading

Successful completion of analytical validation for Clarava™ and Tuteva™

February 15, 2022
Lead products meet comprehensive requirements at CLIA-certified laboratory, representing an important milestone towards commercialisation
Keep Reading

Verici Dx CEO Sara Barrington speaks at Edison Open House: Global Healthcare 2022

January 28, 2022
Sara Barrington, CEO of Verici Dx, interviews with Edison Open House
Keep Reading

Investor Presentation

January 14, 2022
CEO Sara Barrington and CFO David Anderson will provide a live progress and strategy update presentation
Keep Reading

Progress and strategy update

January 12, 2022
Verici Dx provides the following corporate update for the year ended 31 December 2021.
Keep Reading

Clarava and Tuteva complete testing requirements for completion of clinical validation study

January 6, 2022
Primary data analysis of two lead products on track for Q1 2022 read-out
Keep Reading

Verici Dx and Illumina demonstrate the clinical utility of Illumina’s newly launched data platforms for analytics

January 5, 2022
Readiness for launch, accelerated by Illumina Connected Analytics, represents an important milestone in the path to commercialization of Verici Dx’s lead products
Keep Reading

American Medical Association grants Verici Dx two CPT® Codes

January 4, 2022
Verici Dx announces it has been granted CPT® Proprietary Laboratory Analyses (“PLA”) codes
Keep Reading

TR-1: Standard form for notification of major holdings

December 17, 2021
Standard form for notification of major holdings
Keep Reading